FDA and Drug Litigation |
Article: Ziagen & Videx Linked To Increased Risks of Heart AttacksThe U.S. Food and Drug Administration (FDA) is reviewing newly received information on the increased risks of heart attacks for HIV-1 patients who are taking Ziagen or Videx as part of their drug therapy.
Early Communication Warning The FDA has issued an Early Communication warning after it received information from the study The Data Collection on Adverse Events of Anti-HIV Drugs that showed a higher risk of heart attacks in patients infected with HIV-1, the most common type of Human Immunodeficiency Virus, were taking GlaxoSmithKline’s Ziagen (abacavir) or Bristol Myers Squibb’s Videx (didanosine) as part of their drug therapy. Although the FDA has stated that it is still reviewing the information, it recommends that health care professionals should evaluate the potential risks and benefits of each HIV-1 antiretroviral drugs (medications for the treatment of infection by retroviruses, primarily HIV) that patients are taking. To view the FDA’s warning, go to: http://www.fda.gov/cder/drug/early_comm/abacavir.htm/. The study The Data Collection on Adverse Events of Anti-HIV Drugs Study observed 33,347 HIV-1 infected patients in North America, Australia and Europe and found a higher risk of heart attacks amongst those patients who were taking the drugs. As a result, the FDA has said that the products’ labeling may need to be revised. Additional information The FDA has provided the following additional information about the drugs:
Articles & Information:Proposed FDA Warning Requirements Not Consumer Friendly Study Finds Drug Makers Not Reporting All Trial Results Consumer Group Claims Botox Injections Linked To 16 Deaths FDA Gets More Money – But Will It Really Help Consumers? View all articles |